Novo Nordisk, the Danish pharmaceutical company, stated today that it will call an Extraordinary General Meeting (EGM) on November 14, 2025, to install a new board of directors following a strategic deadlock with its main shareholder, the Novo Nordisk Foundation. 

In a statement, outgoing Chair Helge Lund noted that, despite extensive discussions with the Foundation, "it has not been possible to reach a common understanding" on the next board composition. Lund stated that the board recommended a renewal "focussing on the addition of select, new competencies while also maintaining continuity," whereas the Foundation advocated for "a more extensive reconfiguration." Given the Foundation's voting control, the board determined that calling the EGM was in the best interests of both the firm and its shareholders. 

Under the plan, Lund, Vice Chair Henrik Poulsen, and independent directors Laurence Debroux, Andreas Fibig, Sylvie Grégoire, Christina Law, and Martin Mackay will not seek re-election. The remaining board members will be Kasim Kutay (non-independent) and employee-elected directors Elisabeth Dahl Christensen, Liselotte Hyveled, Mette Bøjer Jensen, and Thomas Rantzau. 

The Foundation has presented a slate of fresh nominees for election: former Novo Nordisk CEO Lars Rebien Sørensen as chair, Cees de Jong as vice-chair, and Britt Meelby Jensen, Mikael Dolsten, and Stephan Engels on the board. 

The company's recent troubles provide context for this governance divide. Novo Nordisk, known for its diabetes and obesity therapies, has undergone a makeover due to increased competition from rival Eli Lilly and Company. The restructuring includes a CEO change earlier this year and a planned job loss of 9,000 positions, accounting for around 11% of the workforce. 

According to industry commentators, the board reform signals the Foundation's unwillingness to wait until the annual general meeting in March 2026 and its intention to impose more governance authority. According to one article, the decision to replace more than half of the board stems from worries that the previous board was "too slow in recognising" market trends in obesity and weight-loss therapy. 

The November EGM marks a significant milestone for investors and stakeholders. It represents a transition in both board leadership and the power dynamic between the company's management and the dominant shareholder. While the Foundation highlights the importance of new competences and agility in accelerating growth, critics warn that a heavy-handed restructuring risks undermining board independence and long-term strategic continuity. 

As Novo Nordisk starts on its next chapter, the governance spotlight will be focused not only on its pipeline and commercial success but also on how this high-profile board overhaul influences its culture, decision-making, and future growth path.